The most specific finding is tender or thickened temporal arteries with decreased ... or rarely over the orbits. Giant cell arteritis is a systemic vasculitis and careful attention should be ...

AbbVie’s Rinvoq (upadacitinib) has been granted marketing authorisation by the European Commission (EC) to treat giant cell ...

The European Commission (EC) has granted marketing authorisation for AbbVie's once-a-day treatment Rinvoq (upadacitinib) 15mg ...

RINVOQ is the first and only oral Janus kinase (JAK) inhibitor approved in the European Union (EU) to treat adult patients with giant cell arteritis ... of the temporal and other cranial arteries ...

AbbVie immunology clinical development global head and vice-president Kori Wallace stated: "The CHMP's positive opinion for ...

A total of 209 patients received upadacitinib at a dose of 15 mg, 107 received upadacitinib at a dose of 7.5 mg, and 112 received placebo; 70% of the patients had new-onset giant-cell arteritis ...

AbbVie has picked up another indication for its JAK inhibitor Rinvoq in the EU, becoming the first approved oral therapy for giant cell arteritis (GCA), an autoimmune disease affecting the arteries.

Giant cell arteritis (GCA ... It has been alternatively called cranial arteritis or temporal arteritis, reflecting the most commonly affected vessels. However, this terminology minimizes the ...

AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization to RINVOQ� (upadacitinib; 15 mg, once daily) for the treatment of giant cell arteritis (GCA) in ...